University Of Pittsburgh Researcher Identifies Serum Sex Hormones As Powerful Predictors Of Breast Cancer

February 15, 1999

PITTSBURGH, Feb. 15 -- Results of a study published in the February 16 issue of the Annals of Internal Medicine suggest that in the near future a simple blood test to detect levels of sex hormones could predict which women are at the highest risk of developing breast cancer. With this information, physicians could determine who would be good candidates for medications that can reduce the risk of the disease. Jane A. Cauley, Dr.P.H., associate professor of epidemiology at the University of Pittsburgh's Graduate School of Public Health (GSPH), led the multi-center, federally funded study.

"In our study of older women, we found those with the highest levels of either serum estradiol or testosterone were three times more likely than expected to develop breast cancer," said Dr. Cauley. "This magnitude of risk is much higher than that observed for other breast cancer risk factors."

She explained, "Each year more than 180,000 women are diagnosed with breast cancer in the United States. Although well-established risk factors exist for breast cancer, more than 90 percent of all women have at least one of these factors and, individually, each factor only modestly increases a woman's risk of developing the disease."

The research involved participants from the Study of Osteoporotic Fractures and included 97 women who developed breast cancer and 244 randomly selected controls. All women were white, 65 years of age or older and not receiving estrogen. The estimated incidence of breast cancer was lowest (4 per 10,000 women/year) in women with the lowest blood levels of estradiol and testosterone. Conversely, the incidence of breast cancer was highest (65 per 10,000 women/year) in women with the highest concentrations of both hormones.

This research strengthens previous reports indicating that hormone levels influence the risk of breast cancer, according to Dr. Cauley. "This type of information could help clinicians direct high-risk women to consider chemoprevention for breast cancer," said Dr. Cauley. "Results from the Breast Cancer Prevention Trial and the Multiple Outcomes of Raloxifene Evaluation Trial have shown that certain medications can reduce the incidence of breast cancer."

Unlike previous reports, results of this study showed that testosterone and estradiol independently contributed to breast cancer risk. For many years, researchers have known that estradiol, a metabolic product of estrogen, fuels the growth of some breast cancers. The way that testosterone may contribute to breast cancer growth is unclear at this time, according to Dr. Cauley.

Studies are currently underway to determine whether selective estrogen receptor modifiers, or SERMS, can reduce the incidence of breast cancer in women who have high baseline measurements of estradiol. In addition, studies like the Women's Health Trial have shown that dietary modifications can reduce blood levels of estradiol in post-menopausal women. In another study, the Women's Health Initiative, investigators are waiting to see whether reduced dietary fat will translate into a decrease in the number of breast cancer cases.

Because absolute levels of hormones in older women are low, the study employed extremely sensitive, accurate assays to measure differences among levels in study participants. These sensitive assays are not yet clinically available, according to Dr. Cauley.
For more information on the GSPH department of epidemiology, access our website:

University of Pittsburgh Medical Center

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to